The price of Injective (INJ) surged more than 17% during a broader market upward movement, propelled by fresh institutional and ecosystem developments. The recent momentum follows a revised S-1 filing from 21Shares and a wallet integration designed to expand token accessibility.
21Shares Submits Proposed Injective ETF Update
21Shares filed an S-1 update for its proposed Injective exchange-traded fund, introducing a target staking allocation of 40% to 60% of the fund’s INJ holdings. The proposed staking strategy is adjustable based on liquidity requirements and aims to generate additional yield.
The proposed fund intends to list on Nasdaq under the ticker symbol TINJ, utilizing the FTSE Injective Index as its pricing benchmark. BNY Mellon has been designated as the administrator, transfer agent, and cash custodian. The filing does not confirm regulatory approval or set a final launch date, as the product remains subject to regulatory review and market demand.
Phantom Integration Expands Accessibility
Alongside the ETF filing update, Injective launched on Phantom, allowing users to hold, trade, borrow, and exchange tokens using the wallet's application and web extension. The integration connects Injective to a prominent wallet within the Solana ecosystem, establishing an additional distribution channel for Injective-related assets.
Market Response and Outlook
The 17% price advance reflects short-term momentum driven by ecosystem headlines and broader market strength. Analysts note that sustaining the rally will require continued buying volume and broader market support. While the ETF filing and wallet integration strengthen Injective's market narrative, long-term outcomes will depend on regulatory progress, actual user activity, and ongoing demand for INJ.
